ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2024
Correlation Between Thyroid Hormone and Controlled Attenuation Parameters: A Cross-Sectional Population-Based Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of the present study was to investigate how thyroid hormone levels are related to controlled attenuation parameters (CAP), which may provide insights for understanding the role of these factors in hepatic steatosis. Methods: A total of 3461 participants who underwent CAP diagnosis between 2018 and 2023 were included. The associations between thyroid hormone levels and CAP were evaluated through multiple linear regression, restricted cubic splines (RCS) and threshold effect analyses. Results: Multiple linear regression analysis revealed an inverse relationship between free thyroxine (FT4) and CAP, with a coefficient of -0.855 and a confidence interval of -1.297 to -0.412. The negative connection in a subset examination persisted in males [-0.729 (-1.295, -0.162)] and females [-1.234 (-1.996, -0.473)]. A strong correlation was found between free 3,5,3'-triiodothyronine (FT3) and CAP, with values of 2.182 (1.154, 3.211). Further analysis was conducted on both male [1.626 (0.188, 3.065)] and female [2.835 (1.137, 4.533)] subgroups. In the severe liver steatosis group, there was a significant negative correlation between FT3 and CAP based on the subgroup analysis stratified by the level of liver steatosis [-3.804 (-6.711, -0.898)]. The RCS analysis showed a nonlinear association between FT4 and CAP, with a turning point at 11.14 pmol/L. Conclusion: There was a significant linear and nonlinear relationship between FT4, FT3 and CAP. Thyroid hormones could have a significant impact on liver steatosis, offering fresh perspectives on how to prevent and treat this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.